High-dose Rate Brachytherapy In The Treatment Of Prostate Cancer: Acute Toxicity And Biochemical Behavior Analysis [braquiterapia De Alta Taxa De Dose No Tratamento Do Carcinoma Da Próstata: Análise Da Toxicidade Aguda E Do Comportamento Bioquímico]

dc.creatorBarros Esteves S.C.
dc.creatorZuliani De Oliveira A.C.
dc.creatorCardoso H.
dc.creatorTagawa E.K.
dc.creatorD'Imperio M.
dc.creatorCastelo R.
dc.date2006
dc.date2015-06-30T18:07:33Z
dc.date2015-11-26T14:24:01Z
dc.date2015-06-30T18:07:33Z
dc.date2015-11-26T14:24:01Z
dc.date.accessioned2018-03-28T21:26:06Z
dc.date.available2018-03-28T21:26:06Z
dc.identifier
dc.identifierRadiologia Brasileira. , v. 39, n. 2, p. 127 - 130, 2006.
dc.identifier1003984
dc.identifier10.1590/S0100-39842006000200011
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-33744540634&partnerID=40&md5=c1e63136ac04fb1cc4e88eddb37e4387
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/103171
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/103171
dc.identifier2-s2.0-33744540634
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1245283
dc.descriptionOBJECTIVE: This study focuses on the biochemical response of the following variables: prostate volume, prostate-specific antigen (PSA) value, Gleason scores, staging, the risk of the disease, and hormonotherapy. MATERIALS AND METHODS: In the period between February of 1998 and July of 2001, 46 patients with prostate cancer were treated with radiotherapy, in a combination of teletherapy and high-dose rate brachytherapy (HDR). The age ranged from 51 to 79 years (averaging 66.4 years). T1c stage was the most frequent one: 30 (65%). The Gleason score was below 7 in 78% of the patients. PSA ranged from 3.4 to 33.3, being below 10 in 39% of the cases. The average prostatic volume was 32.3cc. Twenty-eight percent of the patients received hormonotherapy. Teletherapy dose ranged from 45 to 50.4 Gy, associated to four fractions of 4 Gy of HDR. RESULTS: The follow-up period varied from 6 to 43 months. Four patients missed the follow-up and four died (one due to the disease). Out of the 39 patients that were analyzed, 76% presented a less than 1.5 PSA. None of the analyzed variables were found to be of statistical significance (p > 0.05) regarding biochemical control. CONCLUSION: The use of HDR brachytherapy was found to be effective in the treatment of prostate cancer and, in this study, the variables considered as prognostic factors did not interfere in the biochemical control.
dc.description39
dc.description2
dc.description127
dc.description130
dc.descriptionBagshaw, M.A., Cox, R.S., Ramback, J.E., Radiation therapy for localized prostate cancer. Justification by long-term folow-up (1990) Urol Clin North Am, 17, pp. 787-802
dc.descriptionKhan, K., Thompson, W., Bush, S., Stidley, C., Transperineal percutaneous iridium-192 interstitial template implant of the prostate: Results and complications in 321 patients (1992) Int J Radiat Oncol Biol Phys, 22, pp. 935-939
dc.descriptionRubin, P., Wasserman, T.H., International Clinical Trials in Radiation Oncology. The late effects of toxicity scoring (1988) Int JRadiat Oncol Biol Phys, 14 (1 SUPPL.), pp. S29-38
dc.descriptionSchaafsma, J., Osoba, D., The Karnofsky Performance Status Scale re-examined: A cross-validation with the EORTC-C30 (1994) Qual Life Res, 3, pp. 413-424
dc.descriptionZagars, G.K., Pollack, A., Von Eschenbach, A.C., Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen (1995) Int J Radiat Oncol Biol Phys, 33, pp. 23-35
dc.descriptionZagars, G.K., Sherman, N.E., Babaian, R.J., Prostate-specific antigen and external beam radiation therapy in prostate cancer (1991) Cancer, 67, pp. 412-420
dc.descriptionArai, T., Nakano, T., Morita, S., Sakashita, K., Nakamura, Y.K., Fukuhisa, K., High-dose-rate remote after-loading intracavitary radiation therapy for cancer of the uterine cervix. A 20-year experience (1992) Cancer, 69, pp. 175-180
dc.descriptionMartinez, A., Gonzalez, J., Stromberg, J., Conformal prostate brachytherapy: Initial experience of a phase I/II dose-escalating trial (1995) Int J Radiat Oncol Biol Phys, 33, pp. 1019-1027
dc.descriptionOrton, C.G., High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells (2001) Int J Radiat Oncol Biol Phys, 49, pp. 183-189
dc.descriptionKuban, D.A., El-Mahdi, A.M., Schellhammer, P.F., Prostate-especific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer (1995) Int J Radiat Oncol Biol Phys, 32, pp. 307-316
dc.languagept
dc.publisher
dc.relationRadiologia Brasileira
dc.rightsaberto
dc.sourceScopus
dc.titleHigh-dose Rate Brachytherapy In The Treatment Of Prostate Cancer: Acute Toxicity And Biochemical Behavior Analysis [braquiterapia De Alta Taxa De Dose No Tratamento Do Carcinoma Da Próstata: Análise Da Toxicidade Aguda E Do Comportamento Bioquímico]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución